[go: up one dir, main page]

MX2009006795A - Compuestos que tienen tanto actividades de antagonismo de receptor de angiotensina ii como actividades activadoras de receptores activados por proliferizador de peroxisomas gamma. - Google Patents

Compuestos que tienen tanto actividades de antagonismo de receptor de angiotensina ii como actividades activadoras de receptores activados por proliferizador de peroxisomas gamma.

Info

Publication number
MX2009006795A
MX2009006795A MX2009006795A MX2009006795A MX2009006795A MX 2009006795 A MX2009006795 A MX 2009006795A MX 2009006795 A MX2009006795 A MX 2009006795A MX 2009006795 A MX2009006795 A MX 2009006795A MX 2009006795 A MX2009006795 A MX 2009006795A
Authority
MX
Mexico
Prior art keywords
compounds
angiotensin
receptor antagonism
activating activities
ppary
Prior art date
Application number
MX2009006795A
Other languages
English (en)
Inventor
Christopher Franklin Bigge
Agustin Casimiro-Garcia
Lee Chitase
Hud Lawrence Risley
Robert Philip Schaum
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MX2009006795A publication Critical patent/MX2009006795A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan compuestos de fórmula (I) que tienen tanto actividad antagonista de receptor de angiotensina II como actividad agonista de PPARy; (ver fórmula (I)) también se proporcionan composiciones farmacéuticas que comprenden los compuestos y procedimientos de tratamiento de enfermedades con los compuestos incluyendo diabetes tipo 2, resistencia a insulina, hiperinsulinemia, hiperlipidemia, hipertrigliceridemia, síndrome metabólico, fallo cardiaco congestivo, e hipertensión.
MX2009006795A 2006-12-21 2007-12-03 Compuestos que tienen tanto actividades de antagonismo de receptor de angiotensina ii como actividades activadoras de receptores activados por proliferizador de peroxisomas gamma. MX2009006795A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87633406P 2006-12-21 2006-12-21
US97065307P 2007-09-07 2007-09-07
PCT/IB2007/003844 WO2008084303A1 (en) 2006-12-21 2007-12-03 Compounds having both angiotensin ii receptor antagonism and ppary activating activities

Publications (1)

Publication Number Publication Date
MX2009006795A true MX2009006795A (es) 2009-07-03

Family

ID=39284139

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006795A MX2009006795A (es) 2006-12-21 2007-12-03 Compuestos que tienen tanto actividades de antagonismo de receptor de angiotensina ii como actividades activadoras de receptores activados por proliferizador de peroxisomas gamma.

Country Status (9)

Country Link
US (1) US20100029710A1 (es)
EP (1) EP2125806A1 (es)
JP (1) JP2010513457A (es)
KR (1) KR20090091356A (es)
AU (1) AU2007343139A1 (es)
CA (1) CA2671943A1 (es)
MX (1) MX2009006795A (es)
NO (1) NO20092374L (es)
WO (1) WO2008084303A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2420501A4 (en) 2009-04-17 2012-08-29 Kowa Co NOVEL COMPOUND HAVING 3-HETEROARYLPYRIMIDIN-4- (3H) -ONE STRUCTURE AND PHARMACEUTICAL PREPARATION CONTAINING THE SAME
JPWO2010137336A1 (ja) 2009-05-29 2012-11-12 興和株式会社 新規なα−フェノキシベンゼン酢酸誘導体及びこれを含有する医薬
JPWO2011024468A1 (ja) 2009-08-27 2013-01-24 興和株式会社 新規なスルホンアミド誘導体及びこれを含有する医薬
JP5583681B2 (ja) 2009-09-29 2014-09-03 興和株式会社 新規なフェニルピリジン誘導体及びこれを含有する医薬
KR20120123325A (ko) 2009-12-15 2012-11-08 시오노기세야쿠 가부시키가이샤 혈관 내피 리파아제 저해 활성을 갖는 옥사디아졸 유도체
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
EP2575461A4 (en) * 2010-05-24 2013-12-18 Univ Vanderbilt SUBSTITUTED 6-METHYLNICOTINAMIDES USEFUL AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR5
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
PL2687523T3 (pl) 2011-03-14 2016-06-30 Kowa Co Nowa pochodna fenylopirydyny i lek zawierający ją
ES2758841T3 (es) * 2011-05-13 2020-05-06 Celgene Int Ii Sarl Moduladores heterocíclicos selectivos del receptor de la esfingosina-1-fosfato
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013068486A1 (en) 2011-11-08 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of male infertility
US9135515B2 (en) 2012-10-22 2015-09-15 Qiagen Gaithersburg, Inc. Automated pelletized sample vision inspection apparatus and methods
US9212976B2 (en) 2013-03-15 2015-12-15 Qiagen Gaithersburg, Inc. Vision-guided aspiration apparatus and methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338740A (en) * 1993-07-13 1994-08-16 Pfizer Inc. Angiotensin II receptor antagonists
US20030158090A1 (en) * 2001-07-23 2003-08-21 Ulrik Pedersen-Bjergaard Renin-angiotensin system in diabetes mellitus
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure

Also Published As

Publication number Publication date
US20100029710A1 (en) 2010-02-04
JP2010513457A (ja) 2010-04-30
AU2007343139A1 (en) 2008-07-17
NO20092374L (no) 2009-09-15
EP2125806A1 (en) 2009-12-02
WO2008084303A1 (en) 2008-07-17
CA2671943A1 (en) 2008-07-17
KR20090091356A (ko) 2009-08-27

Similar Documents

Publication Publication Date Title
MX2009006795A (es) Compuestos que tienen tanto actividades de antagonismo de receptor de angiotensina ii como actividades activadoras de receptores activados por proliferizador de peroxisomas gamma.
IL184932A0 (en) Glucagon receptor antagonists, preperation and therapeutic uses
WO2010036613A8 (en) Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2008097428A3 (en) Compounds and compositions as modulators of gpr119 activity
EA200901442A1 (ru) Комбинированная терапия соединением, проявляющим активность ингибитора рецептора адф на тромбоцитах
DE602007004324D1 (en) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
MX2009007180A (es) Agonistas del receptor acoplado a la proteina g de la piperidina.
WO2007106181A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2009134574A3 (en) Disubstituted phthalazine hedgehog pathway antagonists
WO2007111864A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
DE602007007473D1 (en) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
WO2007136577A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
NO20070213L (no) Glucagon reseptorantagonister, fremstilling og terapeutiske anvendelser
UA92670C2 (ru) Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе
ECSP12012048A (es) Antagonistas del receptor mineralcorticoide no esteroidal
MX2010001574A (es) Ligandos del receptor cannabinoide.
ATE459619T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
MX2011009506A (es) Antagonista del receptor mineralcorticoide y metodos de uso.
ATE473961T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
NZ609596A (en) Cyclohexane derivative compound
SI1805169T1 (sl) Inhibitorji histamin h3 receptorja, njihova priprava in terapevtske uporabe
JO2827B1 (en) Mineralocorticoid receptor antagonists and methods of use
UA96967C2 (en) Piperidine gpcr agonists
SE0402640D0 (sv) Pharmaceutical use